Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
In the last week, Omicron is credited for 73% of new COVID-19 infections and is accounted for 12.6% of positive cases, making it the most rapidly spreading variant the country has seen yet.
Pfizer has paused screening and dosing of a Phase Ib study of its experimental gene therapy treatment for Duchenne muscular dystrophy following the unexpected death of a patient.
The FDA placed bluebird bio’s clinical trial for its candidate sickle cell disease (SCD) treatment on partial hold for participants under 18 years old.
The government charged Chicago-based Daniel V.T. Catenacci, a medical school professor who served as the lead investigator of the company’s cancer drug bemarituzumab.
After last week’s avalanche of clinical trial news associated with the American Society of Hematology Annual Meeting, there are far fewer announcements, but some companies are getting their news out ahead of the holidays.
ViiV Healthcare announced that the FDA approved Apretude, a long-acting injectable pre-exposure prophylactic option to reduce the risk of sexually acquired HIV-1.
Going through the most newsworthy stories of the year, BioSpace found trends more than one big story, topics that just kept rising again and again. Here’s a look.
Mergers and acquisitions are part of the lifeblood of the pharmaceutical industry, as companies flex their pocketbooks to acquire pipelines and talent to bolster and complement their own programs.
Nasal spray vaccine delivery for COVID-19 has been explored by multiple companies since the beginning of the pandemic.
Moderna has decided to drop the patent application to “allow more time for discussions with the NIH”, which will be aimed at an amicable resolution.
Shares of Coherus BioSciences are climbing in premarket trading after the company announced the FDA greenlit the company’s Humira biosimilar Yusimry.
Biogen announced that effective January 1, 2022, it will cut the wholesale acquisition cost of its Alzheimer’s drug Aducanumab in half from $56,000 to $28,200 per patient per year.